Results 11 to 20 of about 2,352 (153)
Tumefactive Demyelinating Lesion Induced by Infliximab in a Patient With Rheumatoid Arthritis: A Case Report. [PDF]
Clin Case RepABSTRACT Tumor Necrosis Factor‐alpha (TNF‐α) inhibitors have been successfully used to treat rheumatoid arthritis (RA), psoriatic and ankylosing arthritis, and inflammatory bowel disease. While these inhibitors effectively decrease the inflammatory activity of immune‐related disorders, they have been associated with central nervous system (CNS) and ...
Rasul SMS +3 more
europepmc +2 more sources
Longitudinal Brain Atrophy Patterns in Early MOG-Antibody Associated Disease and Relapsing Multiple Sclerosis. [PDF]
Eur J NeurolABSTRACT Background Myelin oligodendrocyte glycoprotein antibody‐associated disease can manifest as a relapsing or monophasic condition. Although several MRI studies have shown evident gray and white matter atrophy compared to healthy controls, little is known about regional brain volume dynamics in myelin oligodendrocyte glycoprotein antibody ...
Ladopoulos T +10 more
europepmc +2 more sources
Tumefactive multiple sclerosis in Taiwan. [PDF]
PLoS ONE, 2013 BACKGROUND: Multiple sclerosis (MS) is less common in Asia, including Taiwan, and some characteristics of MS in Asians differ from those of Caucasians. Tumefactive brain lesion is even rarer in MS patients.
Yi-Chun Kuan +3 more
doaj +1 more source
Neurology International, 2021 Distinguishing between tumefactive demyelinating lesions (TDLs) and brain tumors in multiple sclerosis (MS) can be challenging. A progressive course is highly common with brain tumors in MS and no single neuroimaging technique is foolproof when ...
Chantal Kahovec +2 more
doaj +1 more source
When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis
CNS Oncology, 2021 Oligodendrogliomas are slow-growing tumors that account for 15–20% of gliomas. This case report describes the case of an adult male patient diagnosed initially with tumefactive demyelination and multiple sclerosis, which was subsequently found to be a ...
Breanna Taylor +2 more
doaj +1 more source
Tumefactive: A Rare First presentation of Multiple Sclerosis [PDF]
Disease and Diagnosis, 2018 Tumefactive demyelinating lesions are a rare presentation of multiple sclerosis (MS). Diagnosis of tumefactive is commonly carried out using magnetic resonance image (MRI). Tumefactive diagnosis is difficult because of may similar to the clinical and MRI
Athena Sharifi Razavi +3 more
doaj +1 more source
Frontiers in Neurology, 2021 Fingolimod (FTY) is a disease modifying therapy for relapsing remitting multiple sclerosis (RRMS) which can lead to severe lymphopenia requiring therapy discontinuation in order to avoid adverse events.
Valeria Koska +8 more
doaj +1 more source
Tumefactive demyelinating lesion [PDF]
Neurology, 2007 A previously healthy 31-year-old woman presented with a 2-week history of progressive left hemiparesis. MRI (figure) demonstrated a 3 cm enhancing mass in the right posterior frontal white matter with several smaller lesions in …
Mathew R, Guilfoyle, Ramez W, Kirollos
openaire +2 more sources
Diagnostics, 2020 Magnetic-resonance (MR) imaging is the modality of choice for the evaluation of spinal-cord lesions. However, challenges persist in discriminating demyelinating processes from neoplastic lesions using conventional MR sequences.
Yung Hsu +5 more
doaj +1 more source
Frontiers in Neurology, 2021 Tumefactive demyelinating lesions belong to the rare variants of multiple sclerosis, posing a diagnostic challenge since it is difficult to distinguish them from a neoplasm or other brain lesions and they require a careful differential diagnosis.
Pavel Štourač +11 more
doaj +1 more source